Naslov
A retrospective study comparing abiraterone acetate and enzalutamide in the treatment of patients with metastatic castration-resistant prostate cancer in the University Hospital of Split

Autori
Omrčen Tomislav, Farah Rinat, Hrepić Darijo, Surjan Igor, Vrdoljak Eduard

Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), znanstveni

Izvornik
Book of abstract / - , 2018, 48-48

Skup
14th Central European Oncology Congress

Mjesto i datum
Opatija, Hrvatska, 2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Abirateron, enzalutamide, prostate cancer

Sažetak
Introduction: Metastatic castration resistant prostate cancer (mCRPC) is defined as disease progression, biochemically or radiologically, despite castrate levels of testosterone. The therapeutic armamentarium available today has allowed for extension of patient survival via the use of five indispensable treatments. Among these are docetaxel, cabazitaxel, abiraterone acetate (AA), enzalutamide (ENZ) and radium 223. The addition of these therapies has led to increased overall survival (OS). Objectives: To retrospectively compare the efficacy of AA and ENZ in mCRPC patients in the postdocetaxel setting, in real clinical practice, in terms of biochemical, radiological and clinical progression free survival (i.e. bPFS, rPFS and cPFS, respectively) and OS. We also evaluated the toxicitiy of both agents. Materials and methods: A retrospective cohort study using the data collected from patients’ charts in the Department of Oncology and Radiotherapy in Split. A total of 58 consecutive mCRPC patients treated with AA (1000 mg/day, 1h before or 2h after meal) plus P (2x5 mg) (n=27) and ENZ (160 mg/day) (n=31) from October 2015 until May 2018 in the post-docetaxel setting were included in this study. Patients were treated until there was progression of disease or unacceptable toxicity. In order to stop treatment, two out of three criteria for progression (i.e.biochemical, radiological or clinical) should have been fulfilled. For each cycle patients were evaluated for toxicity, PSA and clinical progression. Patients were evaluated every three cycles for radiological progression with bone scintigraphy, abdominal CT or ultrasound and chest X-ray. Results: Median follow up was 12.8 months. Median OS was not reached (NR) for AA+P patients and was 24 months for ENZ patients, p=0.6878. Median bPFS was 8 months for AA+P patients s and 5.5 months for ENZ patients, p=0.6153.. Median rPFS was 11.5 months for AA+P patients and was 8 months for ENZ patients , p=0.2692. Median cPFS was 15 months for AA+P patients and was 13 months for ENZ patients, p= 0.5592. Discussion: This small retrospective analysis shows the result of treatment of our mCRPC patients in the post-docetaxel setting, with AA + P and ENZ in real clinical practice and it represents evidence of efficacy of these agents beyond randomized clinical trials. Despite the numerical difference in mOS, mbPFS, mrPFS, mcPFS, there was no statistically significant difference found between the two groups of patients. The conclusion is that both drugs were equally effective in mCRPC patients in the post- docetaxel setting with acceptable toxicity profiles for both agents.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA